Automated cultivation and high-throughput screening of 3D cardiac organoids

Cardiovascular disease is the leading cause of death worldwide, claiming 34 lives every minute. Cardiotoxicity is also a significant reason for drug withdrawals during development. To tackle these challenges, Molecular Devices and HeartBeat.Bio have teamed up to provide automated solutions that better mimic human cardiac physiology.

In this presentation, Dr. Florian Fuchs, CTO of HeartBeat.Bio, and Dr. Oksana Sirenko, Senior Manager of Assay Development at Molecular Devices, showcase how automated organoid culture and high-throughput screening are facilitating the effective use of cardioids in drug discovery and preclinical cardiotoxicity testing. Learn how cardioids, automation, and high-throughput workflows are revolutionizing the future of cardiac drug development.

This video was filmed at SLAS Europe 2025.